Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based Dynavax Technologies has partnered with Taiwan-based Medigen Vaccine Biologics to develop an adjuvanted Covid-19 vaccine candidate.
The partners will leverage Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein in combination with Dynavax’s advanced adjuvant CpG 1018.
Medigen’s subunit vaccine is based on the technology licence from the US Vaccine Research Center at National Institutes of Health (NIH).